Pacific Biosciences of California Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名112/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價2.25。中期看,股價處於上升通道。近一個月,市場表現非常差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Pacific Biosciences of California Inc評分
相關信息
行業排名
112 / 207
全市場排名
279 / 4563
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
10
分析師
買入
評級
2.250
目標均價
-3.02%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Pacific Biosciences of California Inc亮點
亮點風險
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
公司代碼PACB
公司Pacific Biosciences of California Inc
CEOHenry (Christian O)
網址https://www.pacb.com/
常見問題
Pacific Biosciences of California Inc(PACB)的當前股價是多少?
Pacific Biosciences of California Inc(PACB)的當前股價是 1.770。
Pacific Biosciences of California Inc 的股票代碼是什麼?
Pacific Biosciences of California Inc的股票代碼是PACB。
Pacific Biosciences of California Inc股票的52週最高點是多少?
Pacific Biosciences of California Inc股票的52週最高點是2.725。
Pacific Biosciences of California Inc股票的52週最低點是多少?
Pacific Biosciences of California Inc股票的52週最低點是0.851。
Pacific Biosciences of California Inc的市值是多少?
Pacific Biosciences of California Inc的市值是534.28M。
Pacific Biosciences of California Inc的淨利潤是多少?
Pacific Biosciences of California Inc的淨利潤為-309.85M。
現在Pacific Biosciences of California Inc(PACB)的股票是買入、持有還是賣出?
根據分析師評級,Pacific Biosciences of California Inc(PACB)的總體評級為買入,目標價格為2.250。
Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是多少
Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是-1.670。